Chikungunya is not endemic in the EU/EEA and the majority of the cases are travellers infected outside of the EU/EEA. When the environmental conditions are favourable, in areas where Ae. albopictus is established, viraemic travel-related cases may generate a local transmission of the virus as demonstrated by the sporadic events of chikungunya virus transmission since 2007.
Hantavirus infections are widely distributed across Europe, with the exception of some Mediterranean countries which reported a very low number of cases.
Childhood immunisation against S. pneumoniae is the most effective public health measure for preventing IPD both among vaccine recipients (direct effect), and among unimmunised populations (indirect ‘herd’ effect).
EU case definition for diarrhoea and haemolytic uremic syndrome (HUS) caused by the epidemic strain Shiga toxin 2-producing Escherichia Coli (STEC) O104:H4
Public health advice on prevention of diarrhoeal illness with special focus on Shiga toxin - producing Escherichia coli (STEC), also called verotoxin - producing E. coli (VTEC) or enterohaemorrhagic E. coli (EHEC)
Outbreak of Shiga toxin - producing Escherichia coli (STEC), also called verotoxin-producing E. coli (VTEC) or enterohaemorrhagic E. coli (EHEC) in 2011
On 14-15 January 2015 an ECDC consultation gathered public health experts, entomologists and epidemiologists from Europe, as well as experts from WHO, CDC and PacNet, to review the EU preparedness to dengue and chikungunya importation and onwards transmission and produce a roadmap towards improved EU preparedness.